AgingResearch.NewsJoin free

Kringle Pharma

CompanyJapanFounded 2001

Wikidata

Kringle Pharma develops one asset, in phase 3 (hepatocyte growth factor in acute spinal cord injury). Mostly protein or enzyme; based in Japan, founded in 2001.

1
Asset
Furthest stage
Phase 3
3
Trials
0
Signals

Pipeline

1

  • hepatocyte growth factor

    Activates MET signaling to promote neuronal survival and tissue repair after spinal cord injury.

    Phase 3, Protein or enzyme, acute spinal cord injury

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials3
  • Signals2

Intelligence